Literature DB >> 27836910

Insights from Therapeutic Studies for PrP Prion Disease.

Kenta Teruya1, Katsumi Doh-Ura1.   

Abstract

Although an effective therapy for prion disease has not yet been established, many advances have been made toward understanding its pathogenesis, which has facilitated research into therapeutics for the disease. Several compounds, including flupirtine, quinacrine, pentosan polysulfate, and doxycycline, have recently been used on a trial basis for patients with prion disease. Concomitantly, several lead antiprion compounds, including compound B (compB), IND series, and anle138b, have been discovered. However, clinical trials are still far from yielding significantly beneficial results, and the findings of lead compound studies in animals have highlighted new challenges. These efforts have highlighted areas that need improvement or further exploration to achieve more effective therapies. In this work, we review recent advances in prion-related therapeutic research and discuss basic scientific issues to be resolved for meaningful medical intervention of prion disease.
Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27836910      PMCID: PMC5334251          DOI: 10.1101/cshperspect.a024430

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  10 in total

1.  Melanin or a Melanin-Like Substance Interacts with the N-Terminal Portion of Prion Protein and Inhibits Abnormal Prion Protein Formation in Prion-Infected Cells.

Authors:  Taichi Hamanaka; Keiko Nishizawa; Yuji Sakasegawa; Ayumi Oguma; Kenta Teruya; Hiroshi Kurahashi; Hideyuki Hara; Suehiro Sakaguchi; Katsumi Doh-Ura
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

2.  Transcriptomic analysis identifies novel potential biomarkers and highlights cilium-related biological processes in the early stages of prion disease in mice.

Authors:  Yong-Chan Kim; Byung-Hoon Jeong
Journal:  Prion       Date:  2022-12       Impact factor: 2.547

Review 3.  Identification of anti-prion drugs and targets using toxicity-based assays.

Authors:  Robert Cc Mercer; David A Harris
Journal:  Curr Opin Pharmacol       Date:  2019-01-23       Impact factor: 5.547

4.  Pyrene conjugation and spectroscopic analysis of hydroxypropyl methylcellulose compounds successfully demonstrated a local dielectric difference associated with in vivo anti-prion activity.

Authors:  Kenta Teruya; Ayumi Oguma; Keiko Nishizawa; Hiroshi Kamitakahara; Katsumi Doh-Ura
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

5.  An antipsychotic drug exerts anti-prion effects by altering the localization of the cellular prion protein.

Authors:  Claudia Stincardini; Tania Massignan; Silvia Biggi; Saioa R Elezgarai; Valeria Sangiovanni; Ilaria Vanni; Michael Pancher; Valentina Adami; Jorge Moreno; Matteo Stravalaci; Giulia Maietta; Marco Gobbi; Alessandro Negro; Jesús R Requena; Joaquín Castilla; Romolo Nonno; Emiliano Biasini
Journal:  PLoS One       Date:  2017-08-07       Impact factor: 3.240

6.  Validation of Revised International Creutzfeldt-Jakob Disease Surveillance Network Diagnostic Criteria for Sporadic Creutzfeldt-Jakob Disease.

Authors:  Neil Watson; Peter Hermann; Anna Ladogana; Angeline Denouel; Simone Baiardi; Elisa Colaizzo; Giorgio Giaccone; Markus Glatzel; Alison J E Green; Stéphane Haïk; Daniele Imperiale; Janet MacKenzie; Fabio Moda; Colin Smith; David Summers; Dorina Tiple; Luana Vaianella; Gianluigi Zanusso; Maurizio Pocchiari; Inga Zerr; Piero Parchi; Jean-Philippe Brandel; Suvankar Pal
Journal:  JAMA Netw Open       Date:  2022-01-04

7.  Pentosan polysulfate induces low-level persistent prion infection keeping measurable seeding activity without PrP-res detection in Fukuoka-1 infected cell cultures.

Authors:  Hanae Takatsuki; Morikazu Imamura; Tsuyoshi Mori; Ryuichiro Atarashi
Journal:  Sci Rep       Date:  2022-05-13       Impact factor: 4.379

8.  Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt-Jakob disease.

Authors:  Bradley R Groveman; Natalia C Ferreira; Simote T Foliaki; Ryan O Walters; Clayton W Winkler; Brent Race; Andrew G Hughson; Gianluigi Zanusso; Cathryn L Haigh
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.996

9.  The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions.

Authors:  Basant A Abdulrahman; Dalia Abdelaziz; Simrika Thapa; Li Lu; Shubha Jain; Sabine Gilch; Stefan Proniuk; Alexander Zukiwski; Hermann M Schatzl
Journal:  Sci Rep       Date:  2017-12-14       Impact factor: 4.379

10.  A Bioluminescent Cell Assay to Quantify Prion Protein Dimerization.

Authors:  Katharina Annick Wüsten; Pasham Parameshwar Reddy; Andrej Smiyakin; Maria Eugenia Bernis; Gültekin Tamgüney
Journal:  Sci Rep       Date:  2018-09-21       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.